Stability of extemporaneously compounded spironolactone suspensions.

Pharmaceutical Development, G.D. Searle & Co., Skokie, IL 60077.
American journal of hospital pharmacy 11/1989; 46(10):2040-2.
Source: PubMed

ABSTRACT The short-term stability of spironolactone in liquid formulations prepared from spironolactone tablets was studied at three temperatures. Suspensions of spironolactone at concentrations of 2.5, 5.0, and 10.0 mg/mL were prepared by grinding film-coated tablets to a fine powder, adding Purified Water, USP, triturating the mixture to form a fine paste, adding Cherry Syrup, NF, and homogenizing the suspension. Drug concentrations were immediately measured by a stability-indicating high-performance liquid chromatographic (HPLC) method. Samples were stored in amber glass prescription bottles at 5 and 30 degrees C in controlled environmental cabinets and at ambient room temperature (20 to 24 degrees C) under intense fluorescent light. After two and four weeks of storage the bottles were shaken, and samples were removed and assayed by HPLC. There was no appreciable loss of spironolactone from the cherry syrup formulations stored for two weeks under the conditions studied. Degradation was less than 5% for samples stored for four weeks. Color and odor of the samples did not change appreciably, and counts of bacteria and fungi remained within acceptable limits. Extemporaneously prepared suspensions of spironolactone in Cherry Syrup, NF, are stable for four weeks under the conditions studied.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Because of easiness and accessibility, the oral route of administration is usually the route of choice for medication delivery, as long as the oral drug form is available and the patients' circumstances allow it.In patients admitted to the intensive care unit this route is frequently altered. This provokes difficulties in swallowing and consequently an enteral feeding catheter must be inserted to supply the patient's nutritional requirements. This catheter is also used for the drug administration, which necessitates opening capsules or crushing pills before dilution. When added to drug-nutrient interactions, this process alters the drug's properties and modifies its pharmacokinetic profile, its pharmacological effect and the intensity of side effects. It can also provoke catheter obstruction. The aim of this study was to establish guidelines for drug administration through enteral feeding catheters. We provide a thorough review of the literature, describe oral drug forms, present a protocol for correct drug administration and provide a guide to the most commonly used drugs in our unit. For each of these drugs we include recommendations on administration and possible alternatives.
    Enfermería Intensiva 01/2001; 12(2):66-79.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pharmacist, both in community and hospital pharmacy practice, is often challenged with the preparation of a liquid dosage form not available commercially for paediatric patients, those adults unable to swallow tablets or capsules and patients who must receive medications via nasogastric or gastrostomy tubes. Recognising the lack of information available to healthcare professionals, a general discussion of the various parameters that may be modified in preparing these dosage forms and a tabulated summary of the dosage forms presented in the literature is described, which, although not exhaustive, will provide information on the formulation and stability of the most commonly prepared extemporaneous liquid dosage forms. An extensive survey of the literature and investigation of 83 liquid dosage forms revealed that stability considerations were of concern for only 7.2% of these liquid dosage forms, extemporaneously prepared from the following commercially available products: captopril, hydralazine hydrochloride, isoniazid, levothyroxine sodium, phenoxybenzamine hydrochloride and tetracycline hydrochloride. Inclusion of the antioxidant, sodium ascorbate in the liquid dosage form for captopril resulted in improved stability at 4 degrees C. Hydralazine hydrochloride, isoniazid and phenoxybenzamine hydrochloride were adversely affected due to interactions with excipients in the formulation, while the effect of the preservative in lowering the pH in a levothyroxine sodium mixture resulted in decreased stability. Interestingly, the instability in these formulations is primarily due to interactions between the drug substance and the excipients rather than degradation of the active pharmaceutical ingredient by standard routes such as oxidation, hydrolysis, photolysis or thermolysis. This low percentage however illustrates the low risk associated with these dosage forms investigated. It may be concluded that when considering the safety and efficacy of liquid dosage forms prepared extemporaneously, it is thus important to consider not only the stability of the drug substance but the entire formulation.
    Journal of Pharmacy and Pharmaceutical Sciences 02/2006; 9(3):398-426. · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Water-soluble derivatives of beta-cyclodextrin have been considered for solubilization of spironolactone in the formulation of a safe liquid preparation for premature infants. The oral absorption of spironolactone was studied in rats to evaluate the need to adjust spironolactone dosage in prospective clinical studies. Spironolactone was administered in solutions of sulphobutyl ether beta-cyclodextrin (SBE7) or dimethyl-beta-cyclodextrin (DM-beta-CyD) and also as spironolactone-containing powder papers (reference preparation). Spironolactone in SBE7 solution was administered intravenously to assess the extent of intestinal absorption from the different formulations. Spironolactone and the metabolites 7alpha-thiospirolactone, 7alpha-thiomethylspirolactone and canrenone were determined in rat serum after intravenous administration of spironolactone. Half-lives for spironolactone, 7alpha-thiomethylspirolactone and canrenone were 0.72 +/- 0.17, 1.5 +/- 0.3 and 2.2 +/- 0.3 h, respectively. Although, according to Cmax values, 7alpha-thiomethylspirolactone was the major serum metabolite in rats, higher AUC (area under the serum concentration-time curve) values were obtained for canrenone. After oral administration of spironolactone the bioavailabilities evaluated from the AUC values of 7alpha-thiomethylspirolactone were 27.5 +/- 9.3%, 81.3 +/- 28.8% and 82.8 +/- 28.6% for powder papers, DM-beta-CyD and SBE7 solutions, respectively. The oral absorption of spironolactone by rats was better after administration of spironolactone in SBE7 and DM-beta-CyD solutions than after administration as powder papers. Both cyclodextrin formulations enhanced spironolactone bioavailability to a similar extent despite some deacetylation of spironolactone in the presence of SBE7. A reduction of spironolactone dosage would be recommended during clinical studies with premature infants. These results indicate that SBE7 could be a safe and suitable excipient for the solubilization of spironolactone in paediatric formulations.
    Journal of Pharmacy and Pharmacology 07/1998; 50(6):611-9. · 2.03 Impact Factor